Anti-hepatitis C virus drugs and kidney

Paul Carrier, Marie Essig, Marilyne Debette-Gratien, Denis Sautereau, Annick Rousseau, Pierre Marquet, Jérémie Jacques, Véronique Loustaud-Ratti, Paul Carrier, Marie Essig, Marilyne Debette-Gratien, Denis Sautereau, Annick Rousseau, Pierre Marquet, Jérémie Jacques, Véronique Loustaud-Ratti

Abstract

Hepatitis C virus (HCV) mainly targets the liver but can also induce extrahepatic manifestations. The kidney may be impacted via an immune mediated mechanism or a cytopathic effect. HCV patients are clearly at a greater risk of chronic kidney disease (CKD) than uninfected patients are, and the presence of CKD increases mortality. Interferon-based therapies and ribavirin are difficult to manage and are poorly effective in end-stage renal disease and hemodialysis. These patients should be given priority treatment with new direct anti-viral agents (DAAs) while avoiding peginterferon and ribavirin. The first results were convincing. To aid in the correct use of these drugs in patients with renal insufficiency, their pharmacokinetic properties and potential renal toxicity must be known. The renal toxicity of these new drugs was not a safety signal in clinical trials, and the drugs are generally efficient in these frail populations. These drugs are usually well tolerated, but recent cohort studies have demonstrated that these new regimens may be associated with renal side effects, especially when using sofosbuvir combinations. HCV, renal diseases and comorbidities are intimately linked. The close monitoring of renal function is required, particularly for at-risk patients (transplanted, HIV-coinfected, CKD, hypertensive or diabetic patients). New DAA regimens, which will soon be approved, will probably change the landscape.

Keywords: Direct anti-viral agents; End-stage renal disease; Hepatitis C; Kidney; Nephrotoxicity.

Conflict of interest statement

Conflict-of-interest statement: All authors have no conflict of interest concerning this work.

References

    1. Wörnle M, Schmid H, Banas B, Merkle M, Henger A, Roeder M, Blattner S, Bock E, Kretzler M, Gröne HJ, et al. Novel role of toll-like receptor 3 in hepatitis C-associated glomerulonephritis. Am J Pathol. 2006;168:370–385.
    1. Fabrizi F, Plaisier E, Saadoun D, Martin P, Messa P, Cacoub P. Hepatitis C virus infection, mixed cryoglobulinemia, and kidney disease. Am J Kidney Dis. 2013;61:623–637.
    1. Carrier P, Chambaraud T, Vong C, Guillaudeau A, Debette-Gratien M, Jacques J, Legros R, Sautereau D, Essig M, Loustaud-Ratti V. Severe renal impairment during triple therapy with telaprevir. Clin Res Hepatol Gastroenterol. 2014;38:e69–e71.
    1. Park H, Adeyemi A, Henry L, Stepanova M, Younossi Z. A meta-analytic assessment of the risk of chronic kidney disease in patients with chronic hepatitis C virus infection. J Viral Hepat. 2015;22:897–905.
    1. Hsu YC, Ho HJ, Huang YT, Wang HH, Wu MS, Lin JT, Wu CY. Association between antiviral treatment and extrahepatic outcomes in patients with hepatitis C virus infection. Gut. 2015;64:495–503.
    1. Lee MH, Yang HI, Lu SN, Jen CL, You SL, Wang LY, Wang CH, Chen WJ, Chen CJ. Chronic hepatitis C virus infection increases mortality from hepatic and extrahepatic diseases: a community-based long-term prospective study. J Infect Dis. 2012;206:469–477.
    1. Petta S, Macaluso FS, Craxì A. Cardiovascular diseases and HCV infection: a simple association or more? Gut. 2014;63:369–375.
    1. Kamar N, Alric L, Izopet J, Rostaing L. Hepatitis C virus and kidney disease. Clin Res Hepatol Gastroenterol. 2013;37:328–333.
    1. Izzedine H, Launay-Vacher V, Bourry E, Brocheriou I, Karie S, Deray G. Drug-induced glomerulopathies. Expert Opin Drug Saf. 2006;5:95–106.
    1. Mauss S, Hueppe D, Alshuth U. Renal impairment is frequent in chronic hepatitis C patients under triple therapy with telaprevir or boceprevir. Hepatology. 2014;59:46–48.
    1. Loustaud-Ratti V, Rousseau A, Carrier P, Vong C, Chambaraud T, Jacques J, Debette-Gratien M, Sautereau D, Essig M. eGFR decrease during antiviral C therapy with first generation protease inhibitors: a clinical significance? Liver Int. 2015;35:71–78.
    1. Coilly A, Fougerou C, De Ledinghen V, Houssel-Debry P, Duvoux C, Di Martino V, Radenne S, Kamar N, D’Alteroche L, Leroy V, et al. G15: The association of sofosbuvir and daclatasvir for treating severe recurrence of HCV infection after liver transplantation: Results from a large french prospective multicentric ANRS CO23 CUPILT cohort. J Hepatol. 2015;62(Suppl 2):S236–7.
    1. Saxena V, Koraishy FM, Sise ME, Lim JK, Schmidt M, Chung RT, Liapakis A, Nelson DR, Fried MW, Terrault NA. Safety and efficacy of sofosbuvir-containing regimens in hepatitis C-infected patients with impaired renal function. Liver Int. 2016;36:807–816.
    1. AFEF. Société Française d᾿Hépatologie, Recommandations sur la prise en charge des hépatites virales C, février 2016. Available from: .
    1. European Association for Study of Liver. EASL Recommendations on Treatment of Hepatitis C 2015. J Hepatol. 2015;63:199–236.
    1. AASLD/IDSA HCV Guidance Panel. Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. Hepatology. 2015;62:932–954.
    1. Roth D, Nelson DR, Bruchfeld A, Liapakis A, Silva M, Monsour H, Martin P, Pol S, Londoño MC, Hassanein T, et al. Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): a combination phase 3 study. Lancet. 2015;386:1537–1545.
    1. Pockros PJ, Reddy KR, Mantry PS, Cohen E, Bennett M, Sulkowski MS, Bernstein DE, Cohen DE, Shulman NS, Wang D, et al. Efficacy of Direct-Acting Antiviral Combination for Patients With Hepatitis C Virus Genotype 1 Infection and Severe Renal Impairment or End-Stage Renal Disease. Gastroenterology. 2016;150:1590–1598.
    1. Glue P, Fang JW, Rouzier-Panis R, Raffanel C, Sabo R, Gupta SK, Salfi M, Jacobs S. Pegylated interferon-alpha2b: pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Hepatitis C Intervention Therapy Group. Clin Pharmacol Ther. 2000;68:556–567.
    1. European Medicines Agency. Résumé des caractéristiques du produit Pegasys. Available from: .
    1. European Medicines Agency. Résumé des caractéristiques du produit Pegintron. Available from: .
    1. Gad SC. 2007. Handbook of Pharmaceutical Biotechnology. John Wiley & Sons;
    1. Wills RJ. Clinical pharmacokinetics of interferons. Clin Pharmacokinet. 1990;19:390–399.
    1. Loustaud-Ratti V, Rousseau A, Marquet P, Denis F, Alain S. Ribavirin in chronic hepatitis C: past and future. Expert Rev Anti Infect Ther. 2009;7:249–253.
    1. European Medicines Agency. Résumé des caractéristiques du produit Rebetol. Available from: .
    1. Coilly A, Dumortier J, Botta-Fridlund D, Latournerie M, Leroy V, Pageaux GP, Agostini H, Giostra E, Moreno C, Roche B, et al. Multicenter Experience with Boceprevir or Telaprevir to Treat Hepatitis C Recurrence after Liver Transplantation: When Present Becomes Past, What Lessons for Future? PLoS One. 2015;10:e0138091.
    1. Antonini TM, Furlan V, Teicher E, Haim-Boukobza S, Sebagh M, Coilly A, Bonhomme-Faivre L, Roque-Afonso AM, Vittecoq D, Samuel D, et al. Therapy with boceprevir or telaprevir in HIV/hepatitis C virus co-infected patients to treat recurrence of hepatitis C virus infection after liver transplantation. AIDS. 2015;29:53–58.
    1. European Medicines Agency. Résumé des caractéristiques du produit Incivo. Available from: .
    1. European Medicines Agency. Résumé des caractéristiques du produit Victrelis. Available from: .
    1. Kunze A, Huwyler J, Camenisch G, Gutmann H. Interaction of the antiviral drug telaprevir with renal and hepatic drug transporters. Biochem Pharmacol. 2012;84:1096–1102.
    1. European Medicines Agency. Résumé des caractéristiques du produit Sovaldi. Available from: .
    1. Kirby BJ, Symonds WT, Kearney BP, Mathias AA. Pharmacokinetic, Pharmacodynamic, and Drug-Interaction Profile of the Hepatitis C Virus NS5B Polymerase Inhibitor Sofosbuvir. Clin Pharmacokinet. 2015;54:677–690.
    1. European Medicines Agency. Résumé des caractéristiques du produit Olysio. Available from: .
    1. European Medicines Agency. Résumé des caractéristiques du produit Daklinza. Available from: .
    1. European Medicines Agency. Résumé des caractéristiques du produit Harvoni. Available from: .
    1. Mogalian E. The Pharmacokinetics of Ledipasvir, an HCV Specific NS5A Inhibitor, in HCV-Uninfected Subjects with Severe Renal Impairment. Available from: .
    1. Mogalian E, German P, Kearney BP, Yang CY, Brainard D, McNally J, Moorehead L, Mathias A. Use of Multiple Probes to Assess Transporter- and Cytochrome P450-Mediated Drug-Drug Interaction Potential of the Pangenotypic HCV NS5A Inhibitor Velpatasvir. Clin Pharmacokinet. 2016;55:605–613.
    1. Mogalian E, Mathias A, Brainard D, Shen G, McNally J, Sajwani K, Robson R, Ries D, Lasseter K, Marbury T. P0712: The pharmacokinetics of GS-5816, a pangenotypic HCV-specific NS5A inhibitor, in HCV-uninfected subjects with severe renal impairment. J Hepatol. 2015;62 Suppl 2:S590–S591.
    1. Gutiérrez F, Fulladosa X, Barril G, Domingo P. Renal tubular transporter-mediated interactions of HIV drugs: implications for patient management. AIDS Rev. 2014;16:199–212.
    1. European Medicines Agency. Résumé des caractéristiques du produit Exviera. Available from: .
    1. European Medicines Agency. Résumé des caractéristiques du produit Viekirax. Available from: .
    1. Khatri A, Dutta S, Marbury TC, Preston RA, Rodrigues L Jr, Wang H, Awni W, Menon RM. Pharmacokinetics and Tolerability of Anti-Hepatitis C Virus Treatment with Ombitasvir, Paritaprevir, Ritonavir, with or Without Dasabuvir, in Subjects with Renal Impairment. Clin Pharmacokinet. 2016 Epub ahead of print.
    1. Sulejmani N, Jafri SM, Gordon SC. Pharmacodynamics and pharmacokinetics of elbasvir and grazoprevir in the treatment of hepatitis C. Expert Opin Drug Metab Toxicol. 2016;12:353–361.
    1. Yeh WW, Caro L, Guo Z, Feng HP, Davis HU, Kozisek M, Stypinski D, Feng C, Mitchell C, Gillespie A, et al. Pharmacokinetics of co-administered HCV protease inhibitor MK-5172 and NS5A inhibitor MK-8742 in volunteers with end-stage renal disease on hemodialysis or severe renal impairment not on hemodialysis. Hepatology. 2014;60 S1:1137A.
    1. Russo MW, Fried MW. Side effects of therapy for chronic hepatitis C. Gastroenterology. 2003;124:1711–1719.
    1. Dimitrov Y, Heibel F, Marcellin L, Chantrel F, Moulin B, Hannedouche T. Acute renal failure and nephrotic syndrome with alpha interferon therapy. Nephrol Dial Transplant. 1997;12:200–203.
    1. Ault BH, Stapleton FB, Gaber L, Martin A, Roy S, Murphy SB. Acute renal failure during therapy with recombinant human gamma interferon. N Engl J Med. 1988;319:1397–1400.
    1. Shah M, Jenis EH, Mookerjee BK, Schriber JR, Baer MR, Herzig GP, Wetzler M. Interferon-alpha-associated focal segmental glomerulosclerosis with massive proteinuria in patients with chronic myeloid leukemia following high dose chemotherapy. Cancer. 1998;83:1938–1946.
    1. Ohta S, Yokoyama H, Wada T, Sakai N, Shimizu M, Kato T, Furuichi K, Segawa C, Hisada Y, Kobayashi K. Exacerbation of glomerulonephritis in subjects with chronic hepatitis C virus infection after interferon therapy. Am J Kidney Dis. 1999;33:1040–1048.
    1. Al Harbi A, Al Ghamdi S, Subaity Y, Khalil A. Interferon-induced acute renal failure in nephrotic syndrome. Nephrol Dial Transplant. 1998;13:1316–1318.
    1. Kanungo S, Tamirisa S, Gopalakrishnan R, Salinas-Madrigal L, Bastani B. Collapsing glomerulopathy as a complication of interferon therapy for hepatitis C infection. Int Urol Nephrol. 2010;42:219–222.
    1. Fisher ME, Rossini M, Simmons E, Harris RC, Moeckel G, Zent R. A woman with chronic hepatitis C infection and nephrotic syndrome who developed multiple renal lesions after interferon alfa therapy. Am J Kidney Dis. 2004;44:567–573.
    1. Jadoul M, Piessevaux H, Ferrant A, Cosyns JP, van Ypersele de Strihou C. Renal thrombotic microangiopathy in patients with chronic myelogenous leukaemia treated with interferon-alpha 2b. Nephrol Dial Transplant. 1995;10:111–113.
    1. Stratta P, Canavese C, Dogliani M, Thea A, Degani G, Mairone L, Vercellone A. Hemolytic-uremic syndrome during recombinant alpha-interferon treatment for hairy cell leukemia. Ren Fail. 1993;15:559–561.
    1. Averbuch SD, Austin HA, Sherwin SA, Antonovych T, Bunn PA, Longo DL. Acute interstitial nephritis with the nephrotic syndrome following recombinant leukocyte a interferon therapy for mycosis fungoides. N Engl J Med. 1984;310:32–35.
    1. Gordon A, Menahem S, Mitchell J, Jenkins P, Dowling J, Roberts SK. Combination pegylated interferon and ribavirin therapy precipitating acute renal failure and exacerbating IgA nephropathy. Nephrol Dial Transplant. 2004;19:2155.
    1. Fahal IH, Murry N, Chu P, Bell GM. Acute renal failure during interferon treatment. BMJ. 1993;306:973.
    1. Quesada JR, Talpaz M, Rios A, Kurzrock R, Gutterman JU. Clinical toxicity of interferons in cancer patients: a review. J Clin Oncol. 1986;4:234–243.
    1. Kurschel E, Metz-Kurschel U, Niederle N, Aulbert E. Investigations on the subclinical and clinical nephrotoxicity of interferon alpha-2B in patients with myeloproliferative syndromes. Ren Fail. 1991;13:87–93.
    1. Al-Wakeel J, Mitwalli A, Tarif N, Al-Mohaya S, Malik G, Khalil M. Role of interferon-alpha in the treatment of primary glomerulonephritis. Am J Kidney Dis. 1999;33:1142–1146.
    1. Lederer E, Truong L. Unusual glomerular lesion in a patient receiving long-term interferon alpha. Am J Kidney Dis. 1992;20:516–518.
    1. Lechner J, Malloth N, Seppi T, Beer B, Jennings P, Pfaller W. IFN-alpha induces barrier destabilization and apoptosis in renal proximal tubular epithelium. Am J Physiol Cell Physiol. 2008;294:C153–C160.
    1. Gresser I, Aguet M, Morel-Maroger L, Woodrow D, Puvion-Dutilleul F, Guillon JC, Maury C. Electrophoretically pure mouse interferon inhibits growth, induces liver and kidney lesions, and kills suckling mice. Am J Pathol. 1981;102:396–402.
    1. Morel-Maroger L, Sloper JC, Vinter J, Woodrow D, Gresser I. An ultrastructural study of the development of nephritis in mice treated with interferon in the neonatal period. Lab Invest. 1978;39:513–522.
    1. Fabrizi F, Aghemo A, Fogazzi GB, Moroni G, Passerini P, D’Ambrosio R, Messa P. Acute tubular necrosis following interferon-based therapy for hepatitis C: case study with literature review. Kidney Blood Press Res. 2013;38:52–60.
    1. Schalm SW, Hansen BE, Chemello L, Bellobuono A, Brouwer JT, Weiland O, Cavalletto L, Schvarcz R, Ideo G, Alberti A. Ribavirin enhances the efficacy but not the adverse effects of interferon in chronic hepatitis C. Meta-analysis of individual patient data from European centers. J Hepatol. 1997;26:961–966.
    1. Kökény S, Papp J, Weber G, Vaszkó T, Carmona-Saez P, Oláh E. Ribavirin acts via multiple pathways in inhibition of leukemic cell proliferation. Anticancer Res. 2009;29:1971–1980.
    1. McHutchison JG, Everson GT, Gordon SC, Jacobson IM, Sulkowski M, Kauffman R, McNair L, Alam J, Muir AJ; PROVE1 Study Team. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med. 2009;360:1827–1838.
    1. Hézode C, Forestier N, Dusheiko G, Ferenci P, Pol S, Goeser T, Bronowicki JP, Bourlière M, Gharakhanian S, Bengtsson L, et al. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med. 2009;360:1839–1850.
    1. McHutchison JG, Manns MP, Muir AJ, Terrault NA, Jacobson IM, Afdhal NH, Heathcote EJ, Zeuzem S, Reesink HW, Garg J, et al. Telaprevir for previously treated chronic HCV infection. N Engl J Med. 2010;362:1292–1303.
    1. Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, Marcellin P, Muir AJ, Ferenci P, Flisiak R, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med. 2011;364:2405–2416.
    1. Kwo PY, Lawitz EJ, McCone J, Schiff ER, Vierling JM, Pound D, Davis MN, Galati JS, Gordon SC, Ravendhran N, et al. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial. Lancet. 2010;376:705–716.
    1. Poordad F, McCone J, Bacon BR, Bruno S, Manns MP, Sulkowski MS, Jacobson IM, Reddy KR, Goodman ZD, Boparai N, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med. 2011;364:1195–1206.
    1. Bacon BR, Gordon SC, Lawitz E, Marcellin P, Vierling JM, Zeuzem S, Poordad F, Goodman ZD, Sings HL, Boparai N, et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med. 2011;364:1207–1217.
    1. Virlogeux V, Pradat P, Bailly F, Funingana G, Gonçalves F, Maynard M, Hartig-Lavie K, Amiri M, Zoulim F. Boceprevir and telaprevir-based triple therapy for chronic hepatitis C: virological efficacy and impact on kidney function and model for end-stage liver disease score. J Viral Hepat. 2014;21:e98–e107.
    1. Karino T, Ozeki I, Hige S, Kimura M, Arakawa T, Nakajima T, Kuwata Y, Sato T, Ohmura T, Toyota J. Telaprevir impairs renal function and increases blood ribavirin concentration during telaprevir/pegylated interferon/ribavirin therapy for chronic hepatitis C. J Viral Hepat. 2014;21:341–347.
    1. Rémy AJ, Lesgourgues B, Nalet B, Causse X, Henrion J, Denis J, Arotçarena R, Hagège H, Pariente A; APROVVIE group of Association Nationale des Gastroentérologues des Hôpitaux Généraux (ANGH) Renal dysfunction associated with telaprevir-containing triple therapy for chronic hepatitis C: is early prediction possible? Eur J Gastroenterol Hepatol. 2014;26:996–1002.
    1. Kozielewicz D, Dybowska D, Karwowska K, Wietlicka-Piszcz M. Renal impairment in patients with chronic hepatitis C treated with first generation protease inhibitors. Expert Opin Drug Saf. 2015;14:1815–1825.
    1. Afdhal N, Zeuzem S, Kwo P, Chojkier M, Gitlin N, Puoti M, Romero-Gomez M, Zarski JP, Agarwal K, Buggisch P, et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med. 2014;370:1889–1898.
    1. Afdhal N, Reddy KR, Nelson DR, Lawitz E, Gordon SC, Schiff E, Nahass R, Ghalib R, Gitlin N, Herring R, et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med. 2014;370:1483–1493.
    1. Kowdley KV, Gordon SC, Reddy KR, Rossaro L, Bernstein DE, Lawitz E, Shiffman ML, Schiff E, Ghalib R, Ryan M, et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med. 2014;370:1879–1888.
    1. Alqahtani SA, Afdhal N, Zeuzem S, Gordon SC, Mangia A, Kwo P, Fried M, Yang JC, Ding X, Pang PS, et al. Safety and tolerability of ledipasvir/sofosbuvir with and without ribavirin in patients with chronic hepatitis C virus genotype 1 infection: Analysis of phase III ION trials. Hepatology. 2015;62:25–30.
    1. Nelson DR, Cooper JN, Lalezari JP, Lawitz E, Pockros PJ, Gitlin N, Freilich BF, Younes ZH, Harlan W, Ghalib R, et al. All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study. Hepatology. 2015;61:1127–1135.
    1. Bhamidimarri KR, Czul F, Peyton A, Levy C, Hernandez M, Jeffers L, Roth D, Schiff E, O’Brien C, Martin P. Safety, efficacy and tolerability of half-dose sofosbuvir plus simeprevir in treatment of Hepatitis C in patients with end stage renal disease. J Hepatol. 2015;63:763–765.
    1. Desnoyer A, Pospai D, Lê MP, Gervais A, Heurgué-Berlot A, Laradi A, Harent S, Pinto A, Salmon D, Hillaire S, et al. Pharmacokinetics, safety and efficacy of a full dose sofosbuvir-based regimen given daily in hemodialysis patients with chronic hepatitis C. J Hepatol. 2016;65:40–47.
    1. Jacobson IM, Dore GJ, Foster GR, Fried MW, Radu M, Rafalsky VV, Moroz L, Craxi A, Peeters M, Lenz O, et al. Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet. 2014;384:403–413.
    1. Manns M, Marcellin P, Poordad F, de Araujo ES, Buti M, Horsmans Y, Janczewska E, Villamil F, Scott J, Peeters M, et al. Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2014;384:414–426.
    1. Sulkowski MS, Vargas HE, Di Bisceglie AM, Kuo A, Reddy KR, Lim JK, Morelli G, Darling JM, Feld JJ, Brown RS, et al. Effectiveness of Simeprevir Plus Sofosbuvir, With or Without Ribavirin, in Real-World Patients With HCV Genotype 1 Infection. Gastroenterology. 2016;150:419–429.
    1. Sulkowski MS, Gardiner DF, Rodriguez-Torres M, Reddy KR, Hassanein T, Jacobson I, Lawitz E, Lok AS, Hinestrosa F, Thuluvath PJ, et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med. 2014;370:211–221.
    1. Leroy V, Dumortier J, Coilly A, Sebagh M, Fougerou-Leurent C, Radenne S, Botta D, Durand F, Silvain C, Lebray P, et al. Efficacy of Sofosbuvir and Daclatasvir in Patients With Fibrosing Cholestatic Hepatitis C After Liver Transplantation. Clin Gastroenterol Hepatol. 2015;13:1993–2001.e1-2.
    1. Wanchoo R, Thakkar J, Schwartz D, Jhaveri KD. Harvoni (Ledipasvir With Sofosbuvir)-Induced Renal Injury. Am J Gastroenterol. 2016;111:148–149.
    1. Zeuzem S, Jacobson IM, Baykal T, Marinho RT, Poordad F, Bourlière M, Sulkowski MS, Wedemeyer H, Tam E, Desmond P, et al. Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med. 2014;370:1604–1614.
    1. Feld JJ, Kowdley KV, Coakley E, Sigal S, Nelson DR, Crawford D, Weiland O, Aguilar H, Xiong J, Pilot-Matias T, et al. Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med. 2014;370:1594–1603.
    1. Poordad F, Hezode C, Trinh R, Kowdley KV, Zeuzem S, Agarwal K, Shiffman ML, Wedemeyer H, Berg T, Yoshida EM, et al. ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med. 2014;370:1973–1982.
    1. Ferenci P, Bernstein D, Lalezari J, Cohen D, Luo Y, Cooper C, Tam E, Marinho RT, Tsai N, Nyberg A, et al. ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV. N Engl J Med. 2014;370:1983–1992.
    1. Andreone P, Colombo MG, Enejosa JV, Koksal I, Ferenci P, Maieron A, Müllhaupt B, Horsmans Y, Weiland O, Reesink HW, et al. ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97% and 100% sustained virologic response with or without ribavirin in treatment-experienced patients with HCV genotype 1b infection. Gastroenterology. 2014;147:359–365.e1.
    1. Fabrizi F. Hepatitis C virus infection and dialysis: 2012 update. ISRN Nephrol. 2013;2013:159760.
    1. Fabrizi F, Takkouche B, Lunghi G, Dixit V, Messa P, Martin P. The impact of hepatitis C virus infection on survival in dialysis patients: meta-analysis of observational studies. J Viral Hepat. 2007;14:697–703.
    1. Fabrizi F, Lunghi G, Andrulli S, Pagliari B, Mangano S, Faranna P, Pagano A, Locatelli F. Influence of hepatitis C virus (HCV) viraemia upon serum aminotransferase activity in chronic dialysis patients. Nephrol Dial Transplant. 1997;12:1394–1398.
    1. Fabrizi F, Martin P, Dixit V, Brezina M, Russell J, Conrad A, Schmid P, Gerosa S, Gitnick G. Detection of de novo hepatitis C virus infection by polymerase chain reaction in hemodialysis patients. Am J Nephrol. 1999;19:383–388.
    1. Alric L, Di-Martino V, Selves J, Cacoub P, Charlotte F, Reynaud D, Piette JC, Péron JM, Vinel JP, Durand D, et al. Long-term impact of renal transplantation on liver fibrosis during hepatitis C virus infection. Gastroenterology. 2002;123:1494–1499.
    1. Roth D, Gaynor JJ, Reddy KR, Ciancio G, Sageshima J, Kupin W, Guerra G, Chen L, Burke GW. Effect of kidney transplantation on outcomes among patients with hepatitis C. J Am Soc Nephrol. 2011;22:1152–1160.
    1. Alavian SM, Tabatabaei SV. Meta-analysis of factors associated with sustained viral response in patients on hemodialysis treated with standard or pegylated interferon for hepatitis C infection. Iran J Kidney Dis. 2010;4:181–194.
    1. Fabrizi F, Ganeshan SV, Lunghi G, Messa P, Martin P. Antiviral therapy of hepatitis C in chronic kidney diseases: meta-analysis of controlled clinical trials. J Viral Hepat. 2008;15:600–606.
    1. Gordon CE, Uhlig K, Lau J, Schmid CH, Levey AS, Wong JB. Interferon for hepatitis C virus in hemodialysis--an individual patient meta-analysis of factors associated with sustained virological response. Clin J Am Soc Nephrol. 2009;4:1449–1458.
    1. Gordon CE, Uhlig K, Lau J, Schmid CH, Levey AS, Wong JB. Interferon treatment in hemodialysis patients with chronic hepatitis C virus infection: a systematic review of the literature and meta-analysis of treatment efficacy and harms. Am J Kidney Dis. 2008;51:263–277.
    1. Kamar N, Chatelut E, Manolis E, Lafont T, Izopet J, Rostaing L. Ribavirin pharmacokinetics in renal and liver transplant patients: evidence that it depends on renal function. Am J Kidney Dis. 2004;43:140–146.
    1. Carriero D, Fabrizi F, Uriel AJ, Park J, Martin P, Dieterich DT. Treatment of dialysis patients with chronic hepatitis C using pegylated interferon and low-dose ribavirin. Int J Artif Organs. 2008;31:295–302.
    1. Deltenre P, Moreno C, Tran A, Ollivier I, Provôt F, Stanke F, Lazrek M, Castel H, Canva V, Louvet A, et al. Anti-viral therapy in haemodialysed HCV patients: efficacy, tolerance and treatment strategy. Aliment Pharmacol Ther. 2011;34:454–461.
    1. Mehawej M, Rostaing L, Alric L, Del Bello A, Izopet J, Kamar N. Boceprevir-Based Triple Antiviral Therapy for Chronic Hepatitis C Virus Infection in Kidney-Transplant Candidates. J Transplant. 2015;2015:159795.
    1. Dumortier J, Guillaud O, Gagnieu MC, Janbon B, Juillard L, Morelon E, Leroy V. Anti-viral triple therapy with telaprevir in haemodialysed HCV patients: is it feasible? J Clin Virol. 2013;56:146–149.
    1. Wiegand J, Maasoumy B, Buggisch P, Buslau A, Schiefke I, Berg T, Wedemeyer H, Sarrazin C, Hinrichsen H. Letter: Telaprevir triple therapy in chronic hepatitis C genotype 1 patients receiving haemodialysis. Aliment Pharmacol Ther. 2014;39:1342–1344.
    1. Knapstein J, Galle PR, Zimmermann T. Antiviral triple therapy with boceprevir in a chronic hepatitis C haemodialysis patient awaiting kidney re-transplantation. Dig Liver Dis. 2014;46:88–89.
    1. Bhamidimarri KR, Gutierrez JA, Grigorian A, Peyton L, Levy C, 0’Brien C, Martin P. Urgent Treatment With Sofosbuvir Based Regimen For Hepatitis C Genotype 1 Patients With Severe Renal Insufficiency (GFR <30ml/min) Available from: .
    1. Nazario HE, Ndungu M, Modi AA. Sofosbuvir and simeprevir in hepatitis C genotype 1-patients with end-stage renal disease on haemodialysis or GFR & lt; 30 ml/min. Liver Int. 2016;36:798–801.
    1. Fabrizi F, Martin P, Dixit V, Messa P. Meta-analysis of observational studies: hepatitis C and survival after renal transplant. J Viral Hepat. 2014;21:314–324.
    1. Bruchfeld A, Wilczek H, Elinder CG. Hepatitis C infection, time in renal-replacement therapy, and outcome after kidney transplantation. Transplantation. 2004;78:745–750.
    1. Kamar N, Mariat C, Delahousse M, Dantal J, Al Najjar A, Cassuto E, Lefrançois N, Cointault O, Touchard G, Villemain F, et al. Diabetes mellitus after kidney transplantation: a French multicentre observational study. Nephrol Dial Transplant. 2007;22:1986–1993.
    1. Scott DR, Wong JK, Spicer TS, Dent H, Mensah FK, McDonald S, Levy MT. Adverse impact of hepatitis C virus infection on renal replacement therapy and renal transplant patients in Australia and New Zealand. Transplantation. 2010;90:1165–1171.
    1. Corouge M, Vallet-Pichard A, Pol S. HCV and the kidney. Liver Int. 2016;36 Suppl 1:28–33.
    1. Viral hepatitis guidelines in hemodialysis and transplantation. Am J Transplant. 2004;4 Suppl 10:72–82.
    1. López-Medrano F, Fernández-Ruiz M, Morales JM, San-Juan R, Cervera C, Carratalá J, Torre-Cisneros J, Gavaldá J, Muñoz P, Len O, Martín-Dávila P, Ramos A, Montejo M, Lumbreras C, Moreno A, Aguado JM; Spanish Network for the Research of Infection in Transplantation/Network of Research in Infectious Diseases (RESITRA/REIPI) Study Group. Impact of hepatitis C virus infection on the risk of infectious complications after kidney transplantation: data from the RESITRA/REIPI cohort. Transplantation. 2011;92:543–549.
    1. Forman JP, Tolkoff-Rubin N, Pascual M, Lin J. Hepatitis C, acute humoral rejection, and renal allograft survival. J Am Soc Nephrol. 2004;15:3249–3255.
    1. Fabrizi F, Lunghi G, Dixit V, Martin P. Meta-analysis: anti-viral therapy of hepatitis C virus-related liver disease in renal transplant patients. Aliment Pharmacol Ther. 2006;24:1413–1422.
    1. Wei F, Liu J, Liu F, Hu H, Ren H, Hu P. Interferon-based anti-viral therapy for hepatitis C virus infection after renal transplantation: an updated meta-analysis. PLoS One. 2014;9:e90611.
    1. Sawinski D, Kaur N, Ajeti A, Trofe-Clark J, Lim M, Bleicher M, Goral S, Forde KA, Bloom RD. Successful Treatment of Hepatitis C in Renal Transplant Recipients With Direct-Acting Antiviral Agents. Am J Transplant. 2016;16:1588–1595.
    1. Kamar N, Marion O, Rostaing L, Cointault O, Ribes D, Lavayssière L, Esposito L, Del Bello A, Métivier S, Barange K, et al. Efficacy and Safety of Sofosbuvir-Based Antiviral Therapy to Treat Hepatitis C Virus Infection After Kidney Transplantation. Am J Transplant. 2016;16:1474–1479.
    1. Gutierrez JA, Carrion AF, Avalos D, O’Brien C, Martin P, Bhamidimarri KR, Peyton A. Sofosbuvir and simeprevir for treatment of hepatitis C virus infection in liver transplant recipients. Liver Transpl. 2015;21:823–830.
    1. Lin MV, Sise ME, Pavlakis M, Hanifi JM, Rutherford AE, Elias N, Heher EC, Curry MP, Riella LV. LP42 : Safety and efficacy of novel antivirals in kidney transplant recipients with chronic hepatitis c virus (HCV) infection. J Hepatol. 2015;62:S284–S285.
    1. Huard G, Kim B, Patel A. Early Safety and Efficacy Profiles of Renal Transplant Recipients with Chronic Hepatitis C Treated with Sofosbuvir and Ribavirin. Available from: .
    1. Forns X, Charlton M, Denning J, McHutchison JG, Symonds WT, Brainard D, Brandt-Sarif T, Chang P, Kivett V, Castells L, et al. Sofosbuvir compassionate use program for patients with severe recurrent hepatitis C after liver transplantation. Hepatology. 2015;61:1485–1494.
    1. Belga S, Doucette KE. Hepatitis C in non-hepatic solid organ transplant candidates and recipients: A new horizon. World J Gastroenterol. 2016;22:1650–1663.
    1. Te H, Ahn J, Schiano T, Diesing A, Aronsohn A, Robertazzi S, Myers L, Satoskar R. O110 : Simeprevir sofosbuvir combination therapy for recurrent genotype-1 hepatitis C in liver transplant recipients : A real-life multicenter experience. J Hepatol. 2015;62:S248.
    1. Naggie S, Cooper C, Saag M, Workowski K, Ruane P, Towner WJ, Marks K, Luetkemeyer A, Baden RP, Sax PE, et al. Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1. N Engl J Med. 2015;373:705–713.
    1. Schwarz K, Murray KF, Rosenthal P, Bansal S, Lin CH, Ni L, Kanwar B, Fraser J, German P, Brainard DM, et al. GS17: High Rates Of Svr12 In Adolescents Treated With The Combination Of Ledipasvir/Sofosbuvir. Proceedings of The International Liver Congress™ 2016 - 51st annual meeting of the European Association for the Study of the Liver; April 13-17, 2016, Barcelona, Spain. J Hepatol. 2016;64:S184–S185.

Source: PubMed

스폰서 및 공동 작업자

건강 상태

약물 개입

3
구독하다